Neoplastic Cell Transformation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression.
|
25333262 |
2014 |
Mammary Neoplasms, Experimental
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression.
|
25333262 |
2014 |
Neoplasm Metastasis
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Furthermore, CDKL2 enhanced primary tumor formation and metastasis in a breast cancer xenograft model.
|
25333262 |
2014 |
Disease Exacerbation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression.
|
25333262 |
2014 |
Ovarian Mucinous Adenocarcinoma
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Testicular Germ Cell Tumor
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor.
|
28604728 |
2017 |
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Furthermore, the methylation of CDKL2 was negatively correlated with its mRNA expression (p < 0.001, r<sub>s</sub> = -0.513), and was associated with gender (p = 0.023), age (p = 0.001) and tumor size (p = 0.016).
|
30292871 |
2019 |
Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Analyses by early age at diagnosis and by estrogen receptor α (ERα) tumor status indicated potential associations for rs6852678 in CDKL2 (OR = 0.32, 95% CI: 0.10-1.00; P(recessive) = 0.044) and rs10878640 in DYRK2 (OR = 2.39, 95% CI: 1.32-4.30; P(dominant) = 0.003), and for rs12765929, rs9836340, rs4707795 in BMPR1A, EPHA3 and EPHA7, respectively (ERα tumor status P(interaction)<0.05).
|
21124932 |
2010 |
Cognition Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Treatment with 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)urea (TPPU), a potent sEH inhibitor, in juvenile offspring from prenatal day (P) 28 to P56 could prevent cognitive deficits and loss of parvalbumin (PV) immunoreactivity in the medial PFC of adult offspring after MIA.
|
30890645 |
2019 |
Status Epilepticus
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Male rats underwent pilocarpine-induced status epilepticus (SE) or sham treatment at P56.
|
31270158 |
2019 |
Impaired cognition
|
0.010 |
Biomarker
|
disease |
BEFREE |
Treatment with 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)urea (TPPU), a potent sEH inhibitor, in juvenile offspring from prenatal day (P) 28 to P56 could prevent cognitive deficits and loss of parvalbumin (PV) immunoreactivity in the medial PFC of adult offspring after MIA.
|
30890645 |
2019 |
Hepatocarcinogenesis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results showed that CDKL2 promoter hypermethylation played an important role in hepatocarcinogenesis and might be a valuable biomarker for HCC diagnosis.
|
30292871 |
2019 |
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Additionally, the mRNA expression levels of CDKL2 were decreased both in HCC tissues and cell lines than those in normal liver tissues (All p < 0.05), and the expression could be upregulated by 5-aza-2'-deoxycytidine treatment in HCC cell lines.
|
30292871 |
2019 |
Acute pancreatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Effects of ω-3 Fatty Acids on Toll-like Receptor 4 and Nuclear Factor κB p56 in the Pancreas of Rats With Severe Acute Pancreatitis.
|
28984787 |
2018 |
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, we conducted this study to explore the clinical effect of CDKL2 in GC.
|
29790675 |
2018 |
Hyperactive behavior
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
These local hyper-methylated patterns are highly consistent: 84 sites (from 61 promoters) are hyper-methylated in all the three studied data sets, including many previously reported genes, such as CDKL2, TBX15 and NKX6-2.
|
27760737 |
2018 |
Stomach Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, we conducted this study to explore the clinical effect of CDKL2 in GC.
|
29790675 |
2018 |
Tumor Cell Invasion
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Cellular studies revealed that CDKL2 overexpression impaired cell proliferation and invasion.
|
29790675 |
2018 |
Myopia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Compared with WT littermates, the A2AR KO mice displayed relative myopia (average difference, 5.1 D between P28 and P35) and associated increases in VC depth and axial length from P28 to P56.
|
20484596 |
2010 |
Angiomyolipoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Tuberin (TSC2) was weak or absent in angiomyolipomas, but present in healthy kidney, whereas, phosphorylated p70 S6 kinase and p56 were present only in angiomyolipomas.
|
12711473 |
2003 |
Cervix carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We detected transcripts initiating from both the P105 and the P56 in primary keratinocytes harboring episomal HPV18 as well as in the HPV 18 positive cervical carcinoma cell lines HeLa, C4-1 and SW756.
|
11765912 |
2001 |